natgillin/translations-raw huggingface dataset:
A method according to clause 8, wherein the data analysis comprises identifying the components of the protein lattice and subtracting them from the image derived in sais step of performing electron microscopy to derive an image of the molecular entities, and performing a single particle reconstruction of the image of the molecular entities. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time, da postupak analize podataka uključuje identifikaciju komponenata proteinske rešetke i njihovo izdvajanje iz slike dobivene u navedenom koraku provedbe elektronske mikroskopije kako bi se dobila slika molekularnih entiteta, te rekonstrukciju izdvojenih čestica slike iz molekularnih entiteta.
A pharmaceutical composition, comprising a monoclonal antibody which binds to a tumor-associated antigen or a part thereof, the tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting of: 
Farmaceutski pripravak za primjenu u postupku liječenja, koja se sastoji od antitijela koje se veže za ekstracelularni dio antigena povezanog s tumorom, Navedeni s tumorom povezani antigen koji ima sekvencu koju kodira nukleinska kiselina koja se odabire iz skupine sastavljene od:
and then converting compound 4 to the compound 
(d) zatim konverziju spoja 4 u spoj i
The compound of claim 1, wherein the compound is selected from the group consisting of: or a pharmaceutically acceptable salt of any of the foregoing, wherein the isotopic enrichment factor for each designated deuterium atom is at least 3500. 
Spoj prema zahtjevu 1, naznačen time da je odabran iz skupine koja sadrži [image] i [image] ili farmaceutski prihvatljiva sol bilo kojeg od prethodno navedenih.
In a preferred embodiment, a sustained release composition containing 10 milligrams of 4-aminopyridine is administered twice daily. 
Upotreba prema zahtjevu 13, naznačena time da je spomenuti sastav primijenjen dvaput dnevno u dozi od 10 miligrama aminopiridina.
The USA patent application No. 
Broj europske prijave patenta:
The method of claim 3 wherein said characteristics comprise geographic information of routing address, time of day, day of week, geographic Information of requester, commercial information associated with said routing address, and characteristics of said plurality of service options. The method of any preceding claim wherein said routing address comprises a phone number. 
Postupak prema patentnom zahtjevu 3, naznačen time, da navedene karakteristike obuhvaćaju geografske informacije o odabranoj adresi za usmjeravanje, koje je doba dana, koji je dan u tjednu, geografske informacije o podnositelju zahtjeva, komercijalne informacije povezane s navedenom odabranom adresom, te karakteristike od navedenog mnoštva uslužnih opcija.
x are the atoms of the element BVI, and 2-x are the atoms of the element AVI. 
X su atomi elementa B", i 2-x su atomi elementa A*'.
Use of a pharmaceutical composition according to any one of claims 1-38 in combination with one or more antidiabetic compounds other than Compound I for the manufacture of a pharmaceutical for treating Type II diabetes, wherein Compound I has the formula 
Upotreba farmaceutske kompozicije prema bilo kojem od patentnih zahtjeva 1-38 u kombinaciji sa jednim ili više antidijabetičnih spojeva koji se razlikuju od spoja I za proizvodnju lijeka za liječenje dijabetesa tipa II, pri čemu spoj I ima formulu 44.
a second QAM mapper configured to demultiplex the interleaved PLP data into cell words and to map the cell words to constellation values; and 
drugi QAM maper (704-0) konfiguriran za demultipleksiranje PLP podataka s umetnutim bitovima u stanične riječi i za mapiranje staničnih riječi u konstelacijske vrijednosti koje odgovaraju PLP podacima;
The method of claim 1, wherein the endogenous 11-cis-retinal deficiency is associated with Age-Related Macular Degeneration, Leber Congenital Amaurosis, Retinitis Punctata Albesciens, Congenital Stationary Night Blindness or Fundus Albipunctatus. 
Upotreba iz patentnog zahtjeva 17 ili 18, naznačena time, da je deficijencija endogenog 11-cis-retinala povezana sa senilnom makularnom degeneracijom, Leberovom kongenitalnim amaurozom (LCA), retinitis punctata albesciens, kongenitalnim stacionarnim noćnim sljepilom ili fundus albipunctatus.
at least one active agent, preferably selected from opioid analgesics; at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000; and 
(1) najmanje jedno aktivno sredstvo koje je odabrano od opioidnih analgetika; (2) najmanje jedan polietilen oksid koji ima, prema Teološkim mjerenjima, približnu molekularnu težinu od najmanje 1,000,000; te
A compound of Formula II: or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein: 
Spoj Formule I: [image] ili njegova farmaceutski prihvatljiva sol, solvat ili stereoizomer, naznačen time, da:
Mill (20) according to Claim 12 or 13, wherein opening of the hatch (42) is automatically controlled depending on the temperature in the rotating mass of waste R . 
Mlin (20) sukladno zahtjevu 3, pri čemu se automatsko otvaranje otvora (42) događa kada je postignut prag temperature ili kada je zabilježeno povećanje gradijenta temperaturnog praga.
A hybrid drive system for vehicle comprising at least an engine, characterized in that it further comprises a hybrid electric drive unit according to any one of claims 1 to 11. 
Hibridni pogonski sustav za vozilo koji se sastoji od barem jednog motora (1), naznačen time što nadalje sadrži hibridnu električnu pogonsku jedinicu prema bilo kojem od zahtjeva 1 do 11.
NO:76 and a light chain region of SEQ. 
NO:76 i područje lakog lanca sa SEQ.
The floating element in accordance with claim 8, wherein, in a position of application, the grooves form a downward slope from the first side face to the second side face. 
Plutajući element (1) prema patentnom zahtjevu 9, naznačen time što, što u položaju primjene, žljebovi (71) tvore nagib prema dolje od prve bočne strane (12) do druge bočne strane (14).
progressively decreasing the concentration of feeder cells in the culture medium so as to obtain a total withdrawal of feeder layer after several passages, and further culturing the cells; obtaining adherent continuous diploid avian cell lines derived from ES cells capable of proliferating in a basal medium in the absence of growth factors, and a feeder layer, and wherein said avian cell lines do not produce replication-competent endogenous retrovirus particles. 
€) progresivno snižavanje koncentracije hranjivih stanica u mediju kulture tako da se dobije potpuno uklanjanje hranjivog sloja nakon nekoliko pasaža, i daljnji uzgoj kulture stanica; f) dobivanje adherentnih kontinuiranih diploidnih ptičjih staničnih linija iz ES stanica koje su sposobne proliferirati u bazalnom mediju bez prisutnosti faktora rasta i hranjivog sloja, i gdje te ptičje stanične linije ne proizvode za replikaciju kompetentne endogene čestice retrovirusa.
Bupropion and trazodone for use in the treatment of sexual pain dysfunction in a subject. 
Bupropion i trazodon naznačen time da je za uporabu za liječenje seksualne disfunkcija zbog boli kod subjekta.
Still more preferred corticosteroids under the present invention are: budesonide, beclomethasone dipropionate, mometasone furoate, ciclesonide, triamcinolone, triamcinolone acetonide, triamcinolone hexaacetonide and fluticasone propionate optionally in the form of their racemates, their enantiomers, their diastereomers and mixtures thereof, and optionally their pharmacologically-compatible acid addition salts. 
Kombinacija u skladu s patentnim zahtjevom 3, naznačena time, da je inhibitor PDE4 odabran iz skupine koju čine cilomilast, roflumilast, denbufilin i tetomilast, po izboru u obliku njihovih racemata, enantiomera, dijastereomera i mješavina navedenog, te, po izboru, njihovih farmakološki kompatibilnih adicijskih soli kiselina.
combining an X-ray projection image with the ultrasound images in 3D space. 
kombiniranje rendgenske projekcije slike s ultrazvučnim slikama u 3D prostoru.
inhibits binding of rabies virus to mammalian cells; or 
(a) inhibira vezanje virusa bjesnoće na stanice sisavca; ili
The composition according to either of Claims 4 or 5, wherein said composition is a dry powder suitable for administration by dry powder inhaler. 
Farmaceutski sastav prema zahtjevu 1 ili zahtjevu 2, gdje je sastav suhi prah pogodan za primjenu putem inhalatora sa suhim prahom.
65.4 26.8 Evaluation of the Antipsychotic Potency of ST1469 and ST1899 and their Respective Desmethyl Derivatives ST2087 and ST2472. 
65,4 26,8 Vrednovanje_antipsihotičnog potencijala ST1469 1 ST1899 te njihovih odgovarajućih desmetil derivata ST2087 1 ST2472.
The pharmaceutical composition for use according to claim 12, wherein the bleeding episode is associated with a disease or condition comprising hemarthrosis, muscle bleed, oral bleed, hemorrhage, hemorrhage into muscles, oral hemorrhage, trauma, trauma capitis (head trauma), gastrointestinal bleeding, intracranial hemorrhage, intraabdominal hemorrhage, intrathoracic hemorrhage, bone fracture, central nervous system bleeding, bleeding in the retropharyngeal space, bleeding in the retroperitoneal space, or bleeding in the illiopsoas sheath. 
Farmaceutski pripravak za uporabu prema zahtjevu 11, naznačen time što je epizoda krvarenja povezana s bolešću ili stanjem koje se sastoji od hemartroze, krvarenja mišića, oralnog krvarenja, krvarenja, krvarenja u mišiće, oralnog krvarenja, trauma, trauma capitis (ozljede glave), gastrointestinalnog krvarenja, intrakranijalnog krvarenja, intraabdominalnog krvarenja, intratorakalnog krvarenja, prijeloma kostiju, krvarenja u središnjem živčanom sustavu, krvarenja u retrofaringealnom prostoru, krvarenja u retroperitonealnom prostoru, ili krvarenja u iliopsoas ovojnici.
The solid cosmetic product according to claim 1, wherein the outer effervescent material comprises sodium bicarbonate in an amount of 45 to 80 wt % based on the outer effervescent material. The solid cosmetic product according to claim 1, wherein the outer effervescent material comprises sodium bicarbonate in an amount of 35 to 75 wt % based on the solid cosmetic product. 
Kruti kozmetički proizvod prema bilo kojem od prethodnih zahtjeva naznačen time da vanjski pjenušavi materijal sadrži natrijev bikarbonat u količini od 45 do 80 masenih % u odnosu na vanjski pjenušavi materijal, te limunsku kiselinu u količini od 20 do 50 masenih % u odnosu na vanjski pjenušavi materijal.
Examples 17 and 18 The following compounds were prepared by the method described in Example 16 using appropriate starting materials. 
Primjeri 718 Slijedeći spojevi napravljeni su postupkom koji je opisan u Primjeru 16 korištenjem odgovarajućih polaznih materijala.
In accordance with the foregoing, the present invention also provides: 
U skladu s gore iznesenim, predloženi izum također osigurava:
The method according to claim 1, wherein the dose is a daily dose in a continuous treatment regimen. 
Uporaba prema zahtjevu 1, naznačena time, da doza lijeka je dnevna doza u stalnom režimu liječenja.
After recovery from surgery, animals were housed individually in a sound-proof recorded room maintaining at appropriate ambient temperature on a 12 h light/dark cycle. 
Nakon oporavka od kirurškog zahvata, životinje su individualno smještene u sobi sa zvučnom izolacijom i snimanjem održavana na prikladnoj ambijentalnoj temperaturi s dvanaest satnim ciklusom svjetlo/tama.
The antibody, antigen-binding fragment thereof, or pharmaceutical composition for use according to claim 14 or 15, wherein the antibody or antigen-binding fragment thereof, or the pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, is for administration to the subject in combination with a second therapeutic agent, optionally wherein the second therapeutic agent comprises a NSAID, a corticosteroid, an antibody to a T-cell co-inhibitor, an antibody to a tumor specific antigen, an antibody to PD-1, an indoleamine-2,3-dioxygelnase inhibitor, an Ang2 inhibitor, a cancer vaccine, an EGFR inhibitor, a TGFB inhibitor, a dietary supplement such as an antioxidant, a VEGF antagonist such as an anti-VEGF antibody, a small molecule kinase inhibitor of VEGF receptor or a VEGF-inhibiting fusion protein, surgery, radiation, a chemotherapeutic agent, a cytotoxic agent, or a combination thereof. 
Antitijelo, njegov fragment koji se vezuje za antigen ili farmaceutski pripravak za primjenu prema patentnom zahtjevu 14 ili 15, naznačen time, što antitijelo ili njegov fragment koji se vezuje za antigen, ili farmaceutski pripravak koji sadrži antitijelo ili njegov fragment koji se vezuje za antigen, služi za primjenu kod subjekta u kombinaciji s drugim terapijskim sredstvom, opcionalno naznačen time, što se drugo terapijsko sredstvo sastoji od nesteroidnog protiupalnog lijeka (NSAID), kortikosteroida, antitijela na koinhibitor T-stanica, antitijela na antigen specifičan za tumor, antitijela na PD-1, inhibitora indoleamin-2,3-dioksigelnaze, inhibitora Ang2, cjepiva protiv raka, inhibitora EGFR-a, inhibitora TGFB, dodatka prehrani kao što je antioksidans, antagonista VEGF-a kao što je anti-VEGF antitijelo, inhibitora mikrocelularne kinaze receptora VEGF-a ili fuzijskog proteina koji inhibira VEGF, kirurškog zahvata, zračenja, kemoterapijskog sredstva, citotoksičnog sredstva ili njihove kombinacije.
A method of forming a compound of formula (IV): wherein R1 in each occurrence is independently selected from H, halogen, amino, C1-5 alkyl, C2-5 alkenyl and C2-5 alkynyl; R2 in each occurrence is independently selected from H, halogen, amino, C1-5 alkyl, C2-5 alkenyl and C2-5 alkynyl; and R4 is C1-5 alkyl; 
R' je u svakom slučaju neovisno odabran od H, halogena, amino, C,.5 alkila, C25 alkenila 1 C2 5 alkinila; R? jeu svakom slučaju neovisno odabran od H, halogena, amino, C1.5 alkila, C2_5 alkenila 1 C2.5 alkinila; postupak sadrži korak reakcije spoja formule (III) sa spojem 2-etilhekanoatna sol: m
green, clear and blue glass. 
od zelenog, prozirnog i plavog stakla.
There is thus provided as a further aspect of the invention a compound of formula (I) or a physiologically acceptable solvate thereof for use in human or veterinary medicine, particularly in the treatment of patients with inflammatory and/or allergic conditions. 
Spoj formule (1), ili njegov fiziološki prihvatljiv solvat, namijenjen upotrebi u liječenju pacijenata u skladu s patentnim zahtjevom 5, naznačen time što upalno i/ili alergijsko stanje je alergijski dermatitis.
represents a single bond, or straight or branched alkylene group having 1 to 8 carbon atoms, or a salt thereof, or a solvate of these. 
W' predstavlja jednostruku vezu, ili ravnu ili razgrananu alkilensku skupinu koja ima 1 do 8 ugljikovih atoma, ili njihovu sol ili njihove solvate. 2.
A compound selected from the group consisting of: and pharmaceutically acceptable salts thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što se bira iz skupine koju čine:
Purified collagenase for use in treating cellulite in a human patient by administration to the collagenous septa network, wherein the collagenase is substantially free of other enzymes, wherein the purified collagenase is injected in a dose comprising at least 10000 ABC units, applied in one or more injections, and wherein the collagenase is purified from the bacterium Clostridium histolyticum. 
Pročišćena kolagenaza za primjenu u terapiji celulita kod ljudi, administriranjem u potkožnu kolagenu mrežu, naznačena time što je kolagenza u biti pročišćena od drugih enzima, pri čemu se pročišćena kolagenaza ubrizgava u dozi od najmanje 1 000 ABC jedinica, primjenjenoj u vidu jedne ili više injekcija i naznačena time što je kolagenaza pročišćena iz bakterije Clostridium histolyticum.
This material was placed in a nitrogen atmosphere furnace which was heated to 950°C. 
Ovaj materijal se stavi u peć sa atmosferom dušika koja se zagrijava na 950%C.
When these cells become desensitized to insulin, the body tries to compensate by producing abnormally high levels of insulin and hyperinsulemia results. 
Kada ove stanice postanu neosjetljive na inzulin, organizam to pokušava nadoknaditi proizvodeći abnormalno visoke razine inzulina, što dovodi do hiperinzulinemije.
The compound of claim 4 wherein A is COOH. The compound of claim 1 selected from the group consisting of 4-(6-hydroxy-3-methylquinolin-2-yl)benzoic acid; 
Spoj ili sol prema zahtjevu 4, naznačen/a time, da A je COOH. 6. Spoj prema zahtjevu 1, naznačen time, da je odabran iz skupine koju čine: 4-(6-hidroksi-3-metilkinolin-2-il)benzoeva kiselina;
Preparation of Nebivolol HCl (I) from Nebivolol Base (IX) Using Ethanol as Reaction Solvent and Purification of Nebivolol HCl (I) ml of ethanol and 3.5 g of hydrochloric acid were added to 10 g of nebivolol base (IX) and the reaction mixture was stirred for 4 h at 28-32° C. The material was filtered, washed with 10.0 ml of ethanol and filtered to dryness. 
Primjer 9 Dobivanje nebivolol HCI (I) iz nebivolol baze (DX) rabeći etanol kao reakcijsko otapalo i pročišćavanje nebivolol HCI no 70 ml etanola i 3,5 g klorovodične kiseline je dodano u 10 g nebivolol baze (IX) te je reakcijska smjesa miješana tijekom 4 sata na 28-32 *C. Materijal je profiltriran, ispran s 10,0 ml etanola i filtirran do suhoće.
These objects are addressed by the FVII or FVIIa variants provided herein. BRIEF DISCLOSURE OF THE INVENTION In a first aspect the present invention relates to a Factor VII (FVII) or Factor VIIa (FVIIa) polypeptide variant having an amino acid sequence comprising 1-15 amino acid modifications relative to human Factor VII (hFVII) or human Factor VIIa (hFVIIa) with the amino acid sequence shown in SEQ ID NO:1, wherein a hydrophobic amino acid residue has been introduced by substitution in position 34. 
Polipeptidna varijanta Faktora VII (FVII) ili Faktora VIIa (FVIIa), naznačena time, da ima amino kiselinsku sekvencu koja se razlikuje u 1-15 amino kiselinskih ostataka u odnosu prema amino kiselinskoj sekvenci humanog Faktora VII (hFVII) ili humanog Faktora VIIa (hFVIlIa) koja je prikazana u SEQ ID NO: 1, pri čemu je negativno nabijeni amino kiselinski ostatak bio uveden supstitucijom u položaju 36 te pri čemu navedena polipeptidna varijanta u svojem aktiviranom obliku ima povećanu FX aktivacijsku aktivnost kada se usporedi sa rekombinantnim humanim Faktorom VIIa.
Figure 11 compares the effect of 42-O-(D-fructosylcarbonyl)rapamycin and rapamycin on platelet aggregation. 
Slika 11 uspoređuje učinak 42-O-(D-fruktozilkarbonil)rapamicina i rapamicina na agregaciju trombocita.
The compound of claim 1 which has formula: or wherein the imidazole ring shown in formula A2 and A4 is optionally substituted with one or more groups independently selected from halo, haloalkyl, cyano, or alkyl; 
(A4) gdje je prsten imidazola prikazan u formuli A2 i A4 po izboru supstituiran sa jednom ili više grupa koje su nezavisno odabrane od halo, haloalkil, cijano, ili alkil; ili njegova farmaceutski prihvatljiva sol.
The method of claim 5, wherein selectively controlling the two or more subsets of thermoelectric coolers further comprises, in response to determining that the temperature of the chamber exceeds the upper threshold of the steady state range: 
aktiviranje (1110) drugog TEH-podskupa od mnoštva TEH, kao odgovor na određivanje stanja u kojem temperatura u komori prelazi gornju granicu raspona ravnomjernog stanja;
Thus, a lozenge having a weight of approximately 2.25 g may have a final weight of approximately 1.50 g. 
Tako, tableta koja ima masu od približno 2.25 g može imati krajnju masu od približno 1.50 g.
0.05 The solution for peritoneal dialysis having the following composition 
Otopina za peritonealnu dijalizu, naznačena time što ima sljedeći sastav: natrij simol/l
which is converted into a compound of formula II by reaction with an anhydrous halogenhydric acid optionally generated in situ. 
F koji se transformira u spoj formule II reakcijom s bezvodnom halogenvodičnom kiselinom po izboru dobivenom in Situ.
A slab as claimed in claim 22, characterised in that the third layer (C) presents a thickness between 30% and 88% of the thickness of the slab (100). 
Ploča kao što je navedena u patentnom zahtjevu 21, naznačena time što treći sloj (C) ima debljinu između 30 % i 88 % debljine ove ploče (100).
The compound of embodiment 16, wherein the substituted or unsubstituted aryl is a substituted or unsubstituted phenyl. 
(a) supstituirani ili nesupstituirani fenil ili supstituirani ili nesupstituirani naftil;
wherein x designates the number of equivalents of sulphuric acid and x is 0.5 to 4, and pharmaceutically acceptable solvates thereof. 
# NH UbSO:Kk H Foenmnula H gdje je x 0.5 do 4, i njeni farmaceutski prihvatljivi solvati.
Portion capsule (1) according to one of the preceding claims, characterized in that the material of the basic element is of such thin design that the realization of the channels on the outer side brings corresponding formations on the inner side. 
Kapsula s porcijom u skladu s jednim od prethodnih zahtjeva, naznačena time da je unutar šupljine postavljen filterski element, koji dijeli šupljinu u prvo područje za držanje sirovog materijala za piće i u drugo područje za držanje ekstrakta za napitak.
a total amount of protein of at least 60% (w/w) on a dry weight basis relative to the total weight of the denatured whey protein composition, 
ukupnu količinu proteina od najmanje 60 % (tež./tež.) na osnovi suhe težine u odnosu na ukupnu težinu pripravka denaturiranog proteina sirutke, -
Method for the control of power fluctuation ramps with power storage systems in intermittent power generation plants according to claim 1, characterized in that the substage of setting the dynamic component of the ramp defined as the slope with which the power in the plant is to be varied in each control cycle, according to the state of charge (SOC) of the power storage system, comprises a stage of filtering dynamic ramps for them not to operate if the plant power is too low or if it is too close to nominal power. 
Postupak kontrole rampi fluktuiranja snage sustavima za pohranu energije u elektranama za intermitentno generiranje snage u skladu s patentnim zahtjevima 1 ili 2, naznačen time što podstadij namještanja dinamične komponente rampe definiran kao nagib pod kojim snaga u elektrani treba varirati u svakom ciklusu kontrole, u skladu sa stanjem napunjenosti (SOC) sustava za pohranu energije, uključuje stadij filtriranja dinamične rampe da elektrane ne rade ako je snaga elektrane preniska ili ako je preblizu nominalnoj snazi.
Twenty hours later, HPLC indicated the same amount of starting material still remaining. 
Dvadeset sati kasnije, HPLC je pokazivao da je ostao još uvijek isti iznos polaznog materijala.
Embodiment No. 10: In yet another embodiment of the present invention the process described in embodiments no. 8 and 9 further incorporate a buffering agent selected from a group comprising Di Sodium Hydrogen Ortho Phosphate, Sodium Hydrogen Ortho Phosphate and the like from about 0.001% (w/w) to 1.00% (w/w), preferably 0.05% (w/w), more preferably 0.5% (w/w). 
Postupak za proizvodnju kreme s fusidinskom kiselinom prema bilo kojem od patentnih zahtjeva 9, 10 1 11, naznačen time, da se nadalje puferski agens dodaje u stupnju a patentnog zahtjeva 9, kod čega se navedeni puferski agens odabire iz skupine koja sadrži dinatrijev hidrogenortofosfat, natrijev hidrogenortofosfat 1 slične, u količini od oko 0,001% (tež.) do 1,00% (tež.), prvenstveno 0,05% (tež.), pogodnije 0,5% (tež.).
A bone plate system for securing a bone plate to bone comprising: a bone screw (600) having a central axis (619); 
PATENTNI ZAHTJEVI Sustav pločica za kosti za pričvršćivanje pločice za kosti na kost koji obuhvaća: vijak za kosti (600) sa središnjom osi (619);
According to the experimental studies, water content in the 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride crystals ranges from traces to 6±0.5%. 
Prema eksperimentalnim studijama, sadržaj vode u 1-[3-[3-(4-klorfenil)propoksilpropil|-piperidin monohidrokloridnom kristalu kreće se u 6 +£0,5 %.